CN101559128A - Externally used medicine for expelling wind and clearing away cold, activating meridians to stop pain and preparation method thereof - Google Patents
Externally used medicine for expelling wind and clearing away cold, activating meridians to stop pain and preparation method thereof Download PDFInfo
- Publication number
- CN101559128A CN101559128A CNA2009101469330A CN200910146933A CN101559128A CN 101559128 A CN101559128 A CN 101559128A CN A2009101469330 A CNA2009101469330 A CN A2009101469330A CN 200910146933 A CN200910146933 A CN 200910146933A CN 101559128 A CN101559128 A CN 101559128A
- Authority
- CN
- China
- Prior art keywords
- radix
- herba
- rhizoma
- medicine
- cortex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides an externally used medicine for expelling wind and clearing away cold, activating meridians to stop pain and a preparation method thereof. The medicine is prepared by 25 types of medicinal materials such as radix aconiti preparata, wild aconite root, nux vomica (processed), epimedium, achyranthes root, notopterygium root, cyrtomium fortunei, phellodendron, zaocys dhumnade, hairy antler, dipsacus root, dark plum, asarum, Chinese ephedra, cassia twig, safflower, acanthopanax, honeysuckle, earth worm, loranthus, licorice, drynaria (scald), anisetree bark, myrrh gum (processed) and red ginseng. The medicine links closely with pathogen and pathogenesis of a disease and a plurality of medicines are compatible reasonably, thus expelling wind and clearing away cold as well as activating meridians to stop pain. As an externally used cataplasm, the medicine is taken through skin, thus avoiding the irritation of an oral preparation to gastrointestinal tract; in addition, relatively slow percutaneous absorption process inevitably greatly mitigates drug toxicity to the whole body. Neither skin sensibility nor skin irritation occurs. Therefore, the transdermal drug delivery of new preparation improves the safety of medicine taking to a certain extent and provides new choices for safe clinical medicine use.
Description
Technical field
The present invention relates to the Chinese medicine formulation art, especially relate to a kind of expelling wind and cold, removing obstruction in the collateral to relieve pain.Be used for arthromyodynia, lumbago and skelalgia, the muscle arthralgia, joint stuffiness, and the external used medicine of scapulohumeral periarthritis, cervical spondylosis, rheumatic arthritis, rheumatoid arthritis and preparation method thereof.
Background technology
This medicine for external use thing is made up of 25-component medicines such as Radix Aconiti, Radix Aconiti Kusnezoffii, Semen Strychni.Have expelling wind and cold, the removing obstruction in the collateral to relieve pain effect is used for arthromyodynia, lumbago and skelalgia, and the muscle arthralgia, joint stuffiness, and scapulohumeral periarthritis, cervical spondylosis, rheumatic arthritis, rheumatoid arthritis are seen above disease person.Since the listing, be subjected to the consistent of patient and approved to have very definite curative effect.Owing to contain Semen Strychni etc. in the prescription poison is arranged, be subjected to certain limitation in the clinical use.And it is as the external cataplasma, has reduced toxic and side effects, has increased safety, proves by pharmacodynamics test, and the external cataplasma still can keep the drug effect of oral formulations.And, Chinese medicine patcher preserve moisture ventilative ageing-resistant, pasting comfortablely, easy to use, zest, anaphylaxis are little, are the first-selected dosage forms of Chinese medicine medicine for external use.
The numbness disease is one of clinical common frdquently encountered disease.Mainly be because body is affected by the cold, exopathogen such as damp and hot, cause meridians to be jammed, QI-blood circulation is lost smooth.Wherein cold-damp resistance network is multiple syndrome.Radix Aconiti, the Radix Aconiti Kusnezoffii of getting Da Xin, big heat, big poison in the event side closed and is monarch's [" Rui Zhutang side " volume five claims two black cream], the Radix Aconiti warming the interior cold expelling that dispels the wind, the cold-damp of both heatable flesh table, the kind numbness disease for the treatment of cold-damp resistance network, the YIN-cold of again can temperature leading to internal organs.Merit tool warming YANG collateral dredging is to open numbness, so remove inside and outside cold-damp; The slightly same Radix Aconiti of Radix Aconiti Kusnezoffii function, but it is longer than and searches wind and remove cold damp eliminating, and its pain relieving eliminating impediment merit is stronger is closed and use it, the logical the exterior and the interior of temperature, and the direct attack cold-damp hinders network disease machine, so be monarch.What diligent Sheng Shi of moderns also likes with Radix Aconiti, Radix Aconiti Kusnezoffii partner treatment cold-damp insensitive impediment, and curative effect is quite apparent.[Zhejiang Journal of Traditional Chinese Medicine 1986, (3): 132] Semen Strychni hardship, cold, merit is arrogated to oneself removing obstruction in the collateral to relieve pain, mass dissipating and swelling eliminating " can search the rheumatism that muscles and bones is gone into joint; the expectorant poison that the flesh side film of dispelling condenses outward " [" surgery is given birth to collection entirely "] especially " it opens meridians, reaches thoroughly that the power in joint is real to outclass his medicine also." [" in the medical science loyalty ginseng west record "] thus with two crows mutually 5, stressing muscles and tendons relaxing to alleviate pain also is monarch.5 with the wet Herba Epimedii that stimulates the menstrual flow, Cornu Cervi Pantotrichum, Herba Asari, Ramulus Cinnamomi, Herba Taxilli, Rhizoma Drynariae, Radix Et Caulis Acanthopanacis Senticosi, Zaocys, Rhizoma Et Radix Notopterygii, Radix Dipsaci, ginseng, Rhizoma Osmundae, the Cortex Illicii mended of group to strengthen the power of three monarch drug warming YANG to expel cold, channels sootheing and network vessel quickening, reducing swelling and alleviating pain; Cold main spasm, dampness hampering qi movement are all easily given birth to the stasis of blood, so get Pheretima, Myrrha, Flos Carthami blood circulation promoting and blood stasis dispelling with the meridians of numbness resistance of leading to.Herba Ephedrae, the mutual hot temperature of Ramulus Cinnamomi are walked table, and lung qi dispersing is a minister with removing dampness altogether, the all medicines of monarch drug mostly are suffering, fragrant, dry strong product, the flavor in consumption impairment of QI Tianjin promotes the production of body fluid and holds back liquid so get Fructus Mume, resides in opening and closes, to prevent the hot dry blood of product impairment of body fluid that looses, the strongly fragrant mechanism of qi of temperature, easily accompany hot and suffocating, so extracting honeysuckle, Cortex Phellodendri heat clearing and damp drying, can prevent the hot temperature of monarch drug fraud too again, be assistant altogether.The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription is for making, though our flavour of a drug are many, how and not assorted, the monarch and his subjects are orderly, and assistant makes clearly demarcated, and eliminating evil is main double setting upright, the clear saturating folding of the assistant convergence of residing again among temperature is logical.So share, all medicines play relaxing muscles and tendons to promote blood circulation altogether, the good effect of the analgesia of dispeling the wind.
Summary of the invention
In order to overcome the deficiencies in the prior art, the invention provides a kind of expelling wind and cold, removing obstruction in the collateral to relieve pain.Be used for arthromyodynia, lumbago and skelalgia, the muscle arthralgia, joint stuffiness, and the external used medicine of scapulohumeral periarthritis, cervical spondylosis, rheumatic arthritis, rheumatoid arthritis and preparation method thereof.This curative effect of medication is definite, and effect has no side effect taking convenience rapidly.
The inventor of Department of Pharmacy of the present invention is according to theory of Chinese medical science and the compound Chinese medicinal preparation that develops through for many years clinical empirical summary, commodity unblocking collaterals to treat arthritis crust by name cloth cream.Medicine of the present invention is to be prepared from by acceptable excipient on the raw material of Chinese medicine of following weight parts and the pharmaceutics:
Radix Aconiti Preparata 7-23 Radix Aconiti Kusnezoffii Preparata 7-23 Semen Strychni (system) 7-23
Herba Epimedii 7-23 Radix Achyranthis Bidentatae 7-23 Rhizoma Et Radix Notopterygii 7-23
Rhizoma Osmundae 7-23 Cortex Phellodendri 7-23 Zaocys 7-23
Cornu Cervi Pantotrichum 4-16 Radix Dipsaci 7-23 Fructus Mume 7-23
Herba Asari 2-10 Herba Ephedrae 7-23 Ramulus Cinnamomi 7-23
Flos Carthami 7-23 Radix Et Caulis Acanthopanacis Senticosi 9.64g Flos Lonicerae 7-23
Pheretima 7-23 Herba Taxilli 7-23 Radix Glycyrrhizae 7-23
Rhizoma Drynariae (scalding) 7-23 Cortex Illicii 7-23 Myrrha (processed) 7-23
Radix Ginseng Rubra 7-23
The weight portion proportion optimization of raw material of Chinese medicine of the present invention:
Radix Aconiti Preparata 7 Radix Aconiti Kusnezoffii Preparatas, 7 Semen Strychni (system) 7
Herba Epimedii 7 Radix Achyranthis Bidentataes 7 Rhizoma Et Radix Notopterygiis 7
Rhizoma Osmundae 7 Cortex Phellodendris 7 Zaocyss 7
Cornu Cervi Pantotrichum 4 Radix Dipsacis 7 Fructus Mumes 7
Herba Asari 2 Herba Ephedraes 7 Ramulus Cinnamomi 7
Flos Carthami 7 Radix Et Caulis Acanthopanacis Senticosis 7 Flos Loniceraes 7
Pheretima 7 Herba Taxillis 7 Radix Glycyrrhizaes 7
Rhizoma Drynariae (scalding) 7 Cortex Illiciis 7 Myrrha (processed) 7
Radix Ginseng Rubra 7
The weight portion proportioning of above-mentioned raw materials medicine is also preferred:
Radix Aconiti Preparata 9.64g Radix Aconiti Kusnezoffii Preparata 9.64g Semen Strychni (system) 9.64g
Herba Epimedii 9.64g Radix Achyranthis Bidentatae 9.64g Rhizoma Et Radix Notopterygii 9.64g
Rhizoma Osmundae 9.64g Cortex Phellodendri 9.64g Zaocys 9.64g
Cornu Cervi Pantotrichum 6.43g Radix Dipsaci 9.64g Fructus Mume 9.64g
Herba Asari 4.82g Herba Ephedrae 9.64g Ramulus Cinnamomi 9.64g
Flos Carthami 9.64g Radix Et Caulis Acanthopanacis Senticosi 9.64g Flos Lonicerae 9.64g
Pheretima 9.64g Herba Taxilli 9.64g Radix Glycyrrhizae 9.64g
Rhizoma Drynariae (scalding) 9.64g Cortex Illicii 9.64g Myrrha (processed) 9.64g
Radix Ginseng Rubra 9.64g
The weight portion proportioning of above-mentioned raw materials medicine is also preferred:
Radix Aconiti Preparata 15 Radix Aconiti Kusnezoffii Preparatas, 15 Semen Strychni (system) 15
Herba Epimedii 15 Radix Achyranthis Bidentataes 15 Rhizoma Et Radix Notopterygiis 15
Rhizoma Osmundae 15 Cortex Phellodendris 15 Zaocyss 15
Cornu Cervi Pantotrichum 12 Radix Dipsacis 15 Fructus Mumes 15
Herba Asari 6 Herba Ephedraes 15 Ramulus Cinnamomi 15
Flos Carthami 15 Radix Et Caulis Acanthopanacis Senticosis 15 Flos Loniceraes 15
Pheretima 15 Herba Taxillis 15 Radix Glycyrrhizaes 15
Rhizoma Drynariae (scalding) 15 Cortex Illiciis 15 Myrrha (processed) 15
Radix Ginseng Rubra 15
The weight portion proportioning of above-mentioned raw materials medicine is also preferred:
Radix Aconiti Preparata 20 Radix Aconiti Kusnezoffii Preparatas, 20 Semen Strychni (system) 20
Herba Epimedii 20 Radix Achyranthis Bidentataes 20 Rhizoma Et Radix Notopterygiis 20
Rhizoma Osmundae 20 Cortex Phellodendris 20 Zaocyss 20
Cornu Cervi Pantotrichum 14 Radix Dipsacis 20 Fructus Mumes 20
Herba Asari 8 Herba Ephedraes 20 Ramulus Cinnamomi 20
Flos Carthami 20 Radix Et Caulis Acanthopanacis Senticosis 20 Flos Loniceraes 20
Pheretima 20 Herba Taxillis 20 Radix Glycyrrhizaes 20
Rhizoma Drynariae (scalding) 20 Cortex Illiciis 20 Myrrha (processed) 20
Radix Ginseng Rubra 20
The weight portion proportioning of above-mentioned raw materials medicine is also preferred:
Radix Aconiti Preparata 23 Radix Aconiti Kusnezoffii Preparatas, 23 Semen Strychni (system) 23
Herba Epimedii 23 Radix Achyranthis Bidentataes 23 Rhizoma Et Radix Notopterygiis 23
Rhizoma Osmundae 23 Cortex Phellodendris 23 Zaocyss 23
Cornu Cervi Pantotrichum 16 Radix Dipsacis 23 Fructus Mumes 23
Herba Asari 10 Herba Ephedraes 23 Ramulus Cinnamomi 23
Flos Carthami 23 Radix Et Caulis Acanthopanacis Senticosis 23 Flos Loniceraes 23
Pheretima 23 Herba Taxillis 23 Radix Glycyrrhizaes 23
Rhizoma Drynariae (scalding) 23 Cortex Illiciis 23 Myrrha (processed) 23
Radix Ginseng Rubra 23
Medicine of the present invention can be carried according to the conventional method such as the water of this area, alcohol extraction etc. is prepared into acceptable capsule on any pharmaceutics, crust cloth preparation, tablet, spray or liniment.The crust cloth preparation dosage form of wherein preferred external
Medicine of the present invention also can be made by the method for being prepared as follows:
Above 25-component medical material, Rhizoma Et Radix Notopterygii, Herba Asari, Myrrha, Ramulus Cinnamomi, Radix Ginseng, Radix Et Caulis Acanthopanacis Senticosi, Cornu Cervi Pantotrichum seven flavors soaked 2 hours earlier, and the reuse vapor distillation extracts volatile oil, and volatile oil, medicinal liquid device are in addition preserved; Medicinal residues and Radix Dipsaci, Rhizoma Drynariae, Radix Aconiti Preparata, grass system crow, Semen Strychni (processed), Cortex Phellodendri, Rhizoma Osmundae, Cortex Illicii, Pheretima, 10 flavor medical materials one such as Herba Taxilli are reinstated 70% ethanol extraction 3 times, and alcohol adding amount is 6 times/time, 1.5 hours/time extraction times.Leach alcohol extract, decompression recycling ethanol is to the device preservation in addition of relative density 1.28-1.30 (50 ℃) extractum.Herba Epimedii, Radix Glycyrrhizae, Radix Achyranthis Bidentatae, Flos Lonicerae, Fructus Mume, Herba Ephedrae, Flos Carthami, Zaocys adds 8 times of water, extracts 3 times, extracts 1.5 hours at every turn.Medicinal liquid merges with the medicinal liquid of carrying the volatile oil medical material, and being evaporated to relative density is 1.045～1.065 (50 ℃), the centrifugal removal of impurity, and supernatant is evaporated to relative density 1.28-1.30 (50 ℃) and merges with alcohol-extracted extract.Technology is made acceptable capsule on the pharmaceutics, crust cloth preparation, tablet, spray or liniment routinely then.
The preparation method of medicine of the present invention is preferred:
Above 25-component medical material, Rhizoma Et Radix Notopterygii, Herba Asari, Myrrha, Ramulus Cinnamomi, Radix Ginseng, Radix Et Caulis Acanthopanacis Senticosi, Cornu Cervi Pantotrichum seven flavors soaked 2 hours earlier, and the reuse vapor distillation extracts volatile oil, and volatile oil, medicinal liquid device are in addition preserved; Medicinal residues and Radix Dipsaci, Rhizoma Drynariae, Radix Aconiti Preparata, grass system crow, Semen Strychni (processed), Cortex Phellodendri, Rhizoma Osmundae, Cortex Illicii, Pheretima, 10 flavor medical materials one such as Herba Taxilli are reinstated 70% ethanol extraction 3 times, and alcohol adding amount is 6 times/time, 1.5 hours/time extraction times.Leach alcohol extract, decompression recycling ethanol is to the device preservation in addition of relative density 1.28-1.30 (50 ℃) extractum.Herba Epimedii, Radix Glycyrrhizae, Radix Achyranthis Bidentatae, Flos Lonicerae, Fructus Mume, Herba Ephedrae, Flos Carthami, Zaocys adds 8 times of water, extracts 3 times, extracts 1.5 hours at every turn.Medicinal liquid merges with the medicinal liquid of carrying the volatile oil medical material, and being evaporated to relative density is 1.045～1.065 (50 ℃), the centrifugal removal of impurity, and supernatant is evaporated to relative density 1.28-1.30 (50 ℃) and merges with alcohol-extracted extract.Took by weighing sodium polyacrylate, carbomer, gelatin, Resina persicae, glycerol, sodium hydroxide, distilled water (3.6: 4.2: 6.0: 9.0: 30: 1.5: 45), make substrate, add volatile oil, azone, propylene glycol each 1%, mud moor gold ethyl ester, propyl ester each 0.05%, EDTA-Na0.01%, Chinese medical concrete, mix into glue, coating, cutting, packing.Promptly get the present invention.
The main pharmacodynamics data of medicine of the present invention
The drug action of research unblocking collaterals to treat arthritis cataplasma aspect anti-soft tissue injury, antiinflammatory, analgesia and blood circulation promoting and blood stasis dispelling.
The test medicine: unblocking collaterals to treat arthritis cataplasma (unblocking collaterals to treat arthritis crust cloth cream is not for containing the unblocking collaterals to treat arthritis cataplasma of excipient), pilot product is provided by the Drug Manufacturing Room of China Academy Of Traditional Chinese Medicine Traditional Chinese Medicine Research Institute, lot number 20050615; WANTONG JINGU PIAN is provided by TongHua WanTong Pharmacy Co., Ltd, lot number 041002.
Anti-soft tissue injury effect: 1. clamp is caused in the experimental therapy of rat skin ecchymosis, unblocking collaterals to treat arthritis cataplasma height, middle dosage (2.4g crude drug/kg, 1.2g crude drug/kg) and unblocking collaterals to treat arthritis tablet (treatment to the rat skin ecchymosis in the 2nd day～the 5th day after administration of 1.2g crude drug/kg) have positive effect (with model group relatively, P＜0.05, P＜0.01); (the 3rd day the time, the skin ecchymosis is compared also be significantly improved (P＜0.05) to unblocking collaterals to treat arthritis cataplasma low dosage with model group after administration for 0.6g crude drug/kg).2. cause in the experimental therapy of rat soft tissue injury with wounding device, unblocking collaterals to treat arthritis cataplasma high dose group (2.4g crude drug/kg) and tablet group (and 1.2g crude drug/kg) hinder the limb degree of injury after wound the 4th day than model group take an evident turn for the better (P＜0.05).Hinder the 5th day unblocking collaterals to treat arthritis cataplasma height in back, middle dosage group (2.4g crude drug/kg, 1.2g crude drug/kg) and tablet group (and 1.2g crude drug/kg) hinder the limb degree of injury all than model group take an evident turn for the better (P＜0.05, P＜0.01).Pathological examination results shows: the high, medium and low dosage group of unblocking collaterals to treat arthritis cataplasma (2.4g crude drug/kg, 1.2g crude drug/kg, 0.6g crude drug/kg) and tablet group (and 1.2g crude drug/kg) can significantly alleviate muscular tissue blood stasis, swelling (with model group relatively, P＜0.05).Mirror shows down: each dosage of unblocking collaterals to treat arthritis cataplasma and WANTONG JINGU PIAN all can significantly reduce damage myocyte's swelling degree (comparing P＜0.01 with model group).
Antiinflammatory action: 1. Oleum Tiglii is caused in the antiinflammatory experiment of mice ear, unblocking collaterals to treat arthritis cataplasma height (2.88g crude drug/kg), middle dosage (1.44g crude drug/kg) and WANTONG JINGU PIAN (1.44g crude drug/kg) to ear swelling all have significant inhibitory effect (with model group relatively, P＜0.05).2. on Carrageenan causes in the antiinflammatory experiment of rat paw edema, ((1.2g crude drug/kg) all can significantly reduce injection back 1h to the high, medium and low dosage of unblocking collaterals to treat arthritis cataplasma for 2.4g crude drug/kg, 1.2g crude drug/kg, 0.6g crude drug/kg) and tablet, 2h, 4h, the foot swelling rate of 6h (comparing P＜0.01) with model group.3. in the experimental therapy to rat assist agent arthritis, for the injection foot, after the freund adjuvant sensitization 1～10 day, (the 2.4g crude drug/kg) significantly suppress foot swelling (compares with model group unblocking collaterals to treat arthritis cataplasma high dose, P＜0.05, P＜0.01), after the sensitization 1～7 day, dosage in the unblocking collaterals to treat arthritis cataplasma (1.2g crude drug/kg) and tablet (1.2g crude drug/kg) significantly suppress foot swelling (with model group relatively, P＜0.05, P＜0.01), in the sensitization later stage, each group all has the trend that suppresses foot swelling, wherein dosage group the 13rd day and model group compare in the unblocking collaterals to treat arthritis cataplasma, obviously suppress foot swelling (P＜0.05), low dose group the 13rd day, the 19th day and model group comparison obviously suppress foot swelling (P＜0.05, P＜0.01), unblocking collaterals to treat arthritis tablet group the 13rd～22 day and model group relatively obviously suppress foot swelling (P＜0.05, P＜0.01).For non-injection foot, unblocking collaterals to treat arthritis cataplasma high dose group significantly suppresses foot swelling in the sensitization later stage (10 days～25 days) and (compares with model group, P＜0.05, P＜0.01), the significantly inhibition foot swelling in the 19th day～25 days of dosage group (is compared with model group in the unblocking collaterals to treat arthritis cataplasma, P＜0.05), unblocking collaterals to treat arthritis cataplasma low dose group significantly suppressed foot swelling on the 25th day and (compares with model group, P＜0.05), unblocking collaterals to treat arthritis tablet group significantly suppressed foot swelling on the 16th～25 day and (compares with model group, P＜0.05, P＜0.01).The thymus of each dosage group, adrenal gland, spleen index and model group relatively do not have marked difference, and unblocking collaterals to treat arthritis cataplasma height, middle dosage group 16-24 days body weight and model group after sensitization relatively do not have significant difference.Unblocking collaterals to treat arthritis cataplasma height, middle dosage group have obvious suppression effect (comparing P＜0.05, P＜0.01 with model group) to the arthritis index of the 19th, 22,25 day rat systemic inflammatory response and periangiitis disease degree.
Analgesic activity: 1. in the hot whipping analgesic experiment of mice tepidarium, high dose unblocking collaterals to treat arthritis cataplasma (1h～6h after the administration of 2.88g crude drug/kg), the whipping time lengthening (compares with matched group, P＜0.05, P＜0.01), analgesic effect is remarkable, in dosage unblocking collaterals to treat arthritis cataplasma (2h～6h after the administration of 1.44g crude drug/kg), analgesic effect significantly (compares with matched group, P＜0.01), unblocking collaterals to treat arthritis cataplasma low dosage (0.72g crude drug/kg) and tablet (after the administration of 1.44g crude drug/kg) 1h～4h analgesic effect significantly (with matched group relatively, P＜0.05).2. in mice acetic acid twisting analgesic experiment, unblocking collaterals to treat arthritis cataplasma height, middle dosage (2.88g crude drug/kg, 1.44g crude drug/kg) and tablet (1.44g crude drug/kg) all can obviously reduce the mouse writhing number of times (with matched group relatively, P＜0.05), analgesic activity is arranged.
Function of promoting blood circulation to disperse blood clots: 1. in the hemorheology experiment, unblocking collaterals to treat arthritis cataplasma height, middle dosage (2.4g crude drug/kg, 1.2g crude drug/kg) significantly reduces platelet aggregation rate (comparing P＜0.01 with model group) and plasma viscosity (comparing P＜0.05 with model group).It is that 10/s, the 50/s whole blood viscosity during with 200/s (is compared with model group that unblocking collaterals to treat arthritis cataplasma high dose can significantly reduce shear rate, P＜0.01), dosage in the unblocking collaterals to treat arthritis cataplasma ((compare with model group by the whole blood viscosity when 1.2g crude drug/kg) can significantly reduce shear rate and is 10/s, 50/s, P＜0.05), three dosage of unblocking collaterals to treat arthritis cataplasma can reduce heat sink proteic content with tablet and (compare with model group, P＜0.05, P＜0.01).2. Dichlorodiphenyl Acetate causes in the experimental therapy that the abdominal cavity capillary permeability raises, and (2.88g crude drug/kg, 1.44g crude drug/kg) significantly reduce capillary permeability (comparing P＜0.01 with model group) for unblocking collaterals to treat arthritis cataplasma height, middle dosage.
Test objective:
The function of unblocking collaterals to treat arthritis cataplasma, cure mainly and carry out main pharmacodynamics research, select several animal models such as soft tissue injury, inflammation, pain, blood stasis for use, confirm effects such as its anti-soft tissue injury, antiinflammatory, analgesia, blood circulation promoting and blood stasis dispelling, effectiveness to this dosage form is made scientific evaluation, instructs clinical application.
Content of the test:
One, the effect of the anti-soft tissue injury of unblocking collaterals to treat arthritis cataplasma
1. the unblocking collaterals to treat arthritis cataplasma causes the therapeutical effect of rat skin ecchymosis to clamp
The rat back depilation, the about 5cm * 4cm of area, with tiger clamp rat depilation district skin, to cause subcutaneous hemorrhage degree of being, area is 4cm * 3cm behind the 24h.After 60 rat modelings, be divided into model control group (giving substrate) at random, positive drug diclofenac group (12mg/kg), the WANTONG JINGU PIAN group (1.2g crude drug/kg), unblocking collaterals to treat arthritis cataplasma height (2.4g crude drug/kg), in (1.2g crude drug/kg), low dose group (0.6g crude drug/kg), begin administration behind the 12h, except that WANTONG JINGU PIAN is gastric infusion, all the other are percutaneous dosing, successive administration 5 days, every day 1 time.By touching and swelling and the ecchymosis situation that disappears is estimated in perusal, and measure residue ecchymosis area during the every day administration, according to the form below is kept the score, and is its ecchymosis order of severity index with total points, and the result organizes a t and checks.
1.1 result
Unblocking collaterals to treat arthritis cataplasma height, middle dosage (2.4g crude drug/kg, 1.2g crude drug/kg) and unblocking collaterals to treat arthritis tablet (treatment to the rat skin ecchymosis in the 2nd day～the 5th day after administration of 1.2g crude drug/kg) have positive effect (with model group relatively, P＜0.05, P＜0.01); (the 3rd day the time, the skin ecchymosis is compared also be significantly improved (P＜0.05) to unblocking collaterals to treat arthritis cataplasma low dosage with model group after administration for 0.6g crude drug/kg).
2, the unblocking collaterals to treat arthritis cataplasma causes the therapeutical effect of rat soft tissue injury to wounding device
2.1 material
Unblocking collaterals to treat arthritis cataplasma (4.797g crude drug/g extractum) is provided lot number 20050615 by the Drug Manufacturing Room of China Academy Of Traditional Chinese Medicine Traditional Chinese Medicine Research Institute; WANTONG JINGU PIAN (0.5588g crude drug/sheet) is provided lot number 041002 by TongHua WanTong Pharmacy Co., Ltd; Diclofenac, Novartis Pharma AG, lot number 05103; Formaldehyde: Xu Dong chemical plant, Beijing produces, lot number: 20051125, and it is standby to be made into 10% concentration; Ethanol: the Beijing Chemical Plant produces, and (dehydrated alcohol lot number: 20051129,95% ethanol lot numbers: it is standby 20050827) to be made into 60%, 70%, 80%, 95%, 100% concentration; Dimethylbenzene: the Beijing Chemical Plant produces, lot number: 20050925; Hematoxylin: Beijing chemical reagents corporation produces, lot number: 20040727; Yihong (eosin): the Beijing Chemical Plant produces, lot number: 20040915; Both respectively are made into dye liquor and do HE dyeing; 56 ℃-58 ℃ of paraffin waxs: Shanghai China Ling Kangfuqixiechang produces lot number: 20051029; Resinene glue: Shanghai Sample Model Factory produces, lot number: 20050802.
2.2 method
Animal sloughs a side calf Mus hair with 10% barium sulfide earlier, [freely fall with weight and to wound the rat leg muscle with wounding device behind the 24h, Height Adjustable, potential energy transfers to 0.18kg/m (quality * weight of potential energy=weight is to the height of limbs)] impact once in the mid calf outside, cause the local soft tissue damage, with " the not broken and interior damage of skin " degree of being, if merging skin injury or fracture person are rejected.60 of the rats of selection modeling success, be divided into six groups at random, i.e. model control group (give substrate), unblocking collaterals to treat arthritis cataplasma height (the 2.4g crude drug/kg), in (the 1.2g crude drug/kg), low dosage (0.6g crude drug/kg) organize, WANTONG JINGU PIAN (1.2g crude drug/kg) organize, positive drug diclofenac (12mg/kg) group, except that WANTONG JINGU PIAN is gastric infusion, all the other are percutaneous dosing, successive administration 5 days, every day 1 time.During the administration, observe performance such as the disease of hindering limb swelling and ecchymosis every day, and rank scores record damage index.
Each treated animal is put to death the back and is dissected, get and dampen 1 of position muscular tissue, be fixed in 10% formalin solution, take out the flowing water flushing after 72 hours, the gradient ethanol dehydration, dimethylbenzene is transparent, the waxdip embedding, section, HE dyeing, resinene glue mounting, the pathological manifestations such as traumatic aseptic inflammation reaction of observation by light microscope wound local organization.The pathology damage degree is made an appraisal, make Ridit and analyze, take a picture.Each organizes all attached color photomicrography of muscular tissue.
2.3 result
((1.2g crude drug/kg) is hindered limb swelling degree the 4th day take an evident turn for the better (comparing P＜0.05 with model group) after wound to unblocking collaterals to treat arthritis cataplasma high dose for 2.4g crude drug/kg) and tablet group.The 5th day unblocking collaterals to treat arthritis cataplasma height, middle dosage after wound (2.4g crude drug/kg, 1.2g crude drug/kg) and tablet group hinder limb swelling degree all than model group take an evident turn for the better (P＜0.05, P＜0.01).
Wound local organization pathologic finding, the perusal result: model group rat muscle tissue has obvious hyperemia, congestion.Positive drug group, the high, medium and low dosage group of unblocking collaterals to treat arthritis cataplasma and tablet group rat muscle tissue are congested, congestion all alleviates (comparing P＜0.05 with model group) to some extent.
Observed result under the mirror: the swelling of the most of muscular tissue large tracts of land of model group, muscular tissue obviously increases slightly, and the profit dish disappears, lose normal muscular arrangement, between matter have subregion muscle fiber color to shoal, a matter inflammatory cell infiltration is based on small lymphocyte, responding property of muscular tissue cell hypertrophy.The high, medium and low dosage group of unblocking collaterals to treat arthritis cataplasma, WANTONG JINGU PIAN group are all significantly improved cellular swelling degree (comparing P＜0.01 with model group).
To muscle swelling degree statistics, do the t check analysis.
Two, the antiphlogistic effect of unblocking collaterals to treat arthritis cataplasma
1, the unblocking collaterals to treat arthritis cataplasma causes the antiinflammatory action of mice ear to Oleum Tiglii
1.1 material:
Mice, the Kunming kind, male, body weight 18～22g is provided by Inst. of Genetics and Development Biology, CAS's animal center, quality certification SCXK (capital) 2002-0006.
1.2 medicine, reagent and instrument
Unblocking collaterals to treat arthritis cataplasma (4.797g crude drug/g extractum) is provided lot number 20050615 by the Drug Manufacturing Room of China Academy Of Traditional Chinese Medicine Traditional Chinese Medicine Research Institute; WANTONG JINGU PIAN (0.5588g crude drug/sheet) is provided lot number 041002 by TongHua WanTong Pharmacy Co., Ltd; Cortisone acetate, Shanghai the 9th pharmaceutical factory, lot number 981002; Dehydrated alcohol, analytical pure, Beijing Chemical Plant, lot number 20010209; Ether, analytical pure, Red Star chemical plant, Beijing, lot number 990402.
Electronic balance, LIBROR EB-280M-22, day island proper Tianjin instrument company.
1.3 method.
60 of mices, stratified random is divided into model control group (giving substrate), unblocking collaterals to treat arthritis cataplasma height, in, low dose group (2.88g crude drug/kg, 1.44g crude drug/kg, 0.72g crude drug/kg), WANTONG JINGU PIAN group (1.44g crude drug/kg) and positive drug cortisone acetate group (25mg/kg), wherein removing positive drug is lumbar injection, outside the WANTONG JINGU PIAN gastric infusion, all the other are percutaneous dosing, successive administration 3 days, every day 1 time, behind the last administration 1h, (Oleum Tiglii: ethanol: ether=0.2: 2: 7.8) 50 μ l/ only put to death behind the 4h to smear 2% Oleum Tiglii at the left side auricle, rustless steel blunderbuss blunderbuss bottom left auris dextra exterior feature with diameter 8mm, weigh, calculate the ear swelling rate, organize a t check.Ear swelling rate computing formula is as follows:
Ear swelling rate=(left ear weight-auris dextra is heavy)/auris dextra heavy * 100%
1.4 result
Unblocking collaterals to treat arthritis cataplasma height (2.88g crude drug/kg), middle dosage (1.44g crude drug/kg) and WANTONG JINGU PIAN (1.44g crude drug/kg) to ear swelling all have significant inhibitory effect (with model group relatively, P＜0.05).
2, unblocking collaterals to treat arthritis cataplasma on Carrageenan causes the therapeutical effect of rat paw edema
2.1 material
Animal: the SD rat, male, body weight 190～210g is provided by the department of the Chinese Academy of Sciences of Department Of Medicine, Peking University's laboratory animal section.The quality certification number: SCXK (capital) 2002-0001.
2.2 medicine and reagent
Unblocking collaterals to treat arthritis cataplasma (4.797g crude drug/g extractum) is provided lot number 20050615 by the Drug Manufacturing Room of China Academy Of Traditional Chinese Medicine Traditional Chinese Medicine Research Institute; WANTONG JINGU PIAN (0.5588g crude drug/sheet) is provided lot number 041002 by TongHua WanTong Pharmacy Co., Ltd; Diclofenac, Novartis Pharma AG, lot number 05103; Carrageenin, Sigma company, lot number 121K1653.
2.3 method
60 of rats, stratified random is divided into model control group (giving substrate), unblocking collaterals to treat arthritis cataplasma height, in, low dose group (2.4g crude drug/kg, 1.2g crude drug/kg, 0.6g crude drug/kg), the WANTONG JINGU PIAN group (1.2g crude drug/kg) and positive drug diclofenac group (the suitable 12mg diclofenac sodium of 1.2g cream/kg/kg), except that the WANTONG JINGU PIAN group is gastric infusion, all the other are percutaneous dosing, successive administration 3 days, every day 1 time, behind the last administration 1h, at the carrageenin 100 μ l of its right hind foot sole of the foot portion subcutaneous injection 1%, respectively at injection back 1h, 2h, 4h, 6h calculates the foot swelling rate with self-control tape measuring swelling foot sole of the foot portion girth, organizes a t check.Computing formula is as follows:
Foot swelling rate=(injection metapedes sole of the foot girth-injection front foot sole of the foot girth)/injection front foot sole of the foot girth * 100%
2.4 result
The high, medium and low dosage of unblocking collaterals to treat arthritis cataplasma (2.4g crude drug/kg, 1.2g crude drug/kg, 0.6g crude drug/kg) and tablet (1.2g crude drug/kg) all can significantly reduce injection back 1h, 2h, 4h, the foot swelling rate of 6h (with model group relatively, P＜0.01).
3, the unblocking collaterals to treat arthritis cataplasma is to the influence of rat assist agent arthritis
3.1 method
60 of rats, stratified random are divided into model control group (give substrate), the high, medium and low dosage group of unblocking collaterals to treat arthritis cataplasma (2.4g crude drug/kg, 1.2g crude drug/kg, 0.6g crude drug/kg), WANTONG JINGU PIAN group (1.2g crude drug/kg) and positive drug diclofenac group (12mg/kg).Wherein the WANTONG JINGU PIAN group is an oral administration, all the other are percutaneous dosing, administration is 24 days altogether, every day 1 time, behind first day administration 1h, measure the two hind leg foot of each rat sole of the foot portion girth, then only at its right hind foot sole of the foot subcutaneous injection Fu Shi of portion Freund's complete adjuvant 100 μ l/, respectively at injection back different number of days weighing rat body weight, measure bilateral foot sole of the foot portion girth, observe rat body inflammatory reaction and periangiitis disease degree simultaneously, calculate arthritis index, comprehensively judge drug effect by These parameters, organize a t check.
After administration was measured rat body weight, joint girth and arthritis index on the 24th day, put to death rat, get thymus, spleen and adrenal gland and weigh, calculate organ coefficient (mg internal organs weight/g body weight).
3.2 result
In experimental therapy to rat assist agent arthritis, for the injection foot, after the freund adjuvant sensitization 1～10 day, (the 2.4g crude drug/kg) significantly suppress foot swelling (compares with model group unblocking collaterals to treat arthritis cataplasma high dose, P＜0.05, P＜0.01), after the sensitization 1～7 day, dosage in the unblocking collaterals to treat arthritis cataplasma (1.2g crude drug/kg) and WANTONG JINGU PIAN (1.2g crude drug/kg) significantly suppress foot swelling (with model group relatively, P＜0.05, P＜0.01), in the sensitization later stage, each group all has the trend that suppresses foot swelling, wherein dosage group the 13rd day and model group compare in the unblocking collaterals to treat arthritis cataplasma, obviously suppress foot swelling (P＜0.05), low dose group the 13rd day, the 19th day and model group comparison obviously suppress foot swelling (P＜0.05, P＜0.01), WANTONG JINGU PIAN group the 13rd～22 day and model group relatively obviously suppress foot swelling (P＜0.05, P＜0.01).For non-injection foot, unblocking collaterals to treat arthritis cataplasma high dose group significantly suppresses foot swelling in the sensitization later stage (10 days～25 days) and (compares with model group, P＜0.05, P＜0.01), the significantly inhibition foot swelling in the 19th day～25 days of dosage group (is compared with model group in the unblocking collaterals to treat arthritis cataplasma, P＜0.05), unblocking collaterals to treat arthritis cataplasma low dose group significantly suppressed foot swelling on the 25th day and (compares with model group, P＜0.05), unblocking collaterals to treat arthritis tablet group significantly suppressed foot swelling on the 16th～25 day and (compares with model group, P＜0.05, P＜0.01).
The thymus of each dosage group, adrenal gland, spleen index and model group relatively do not have marked difference, unblocking collaterals to treat arthritis cataplasma height (2.4g crude drug/kg), in (1.2g crude drug/kg), low (0.6g crude drug/kg) relatively do not have significant difference with model group after the dosage group body weight sensitization.Unblocking collaterals to treat arthritis cataplasma high dose (the 2.4g crude drug/kg) (compare with model group by group the 19th, 22,25 day remarkable arthritis index that reduces rat model after sensitization, P＜0.05, P＜0.01), (the 1.2g crude drug/kg) group significantly reduced the arthritis index (comparing P＜0.05 with model group) of rat model on the the 22nd, 25 day to middle dosage after sensitization.(1.2g crude drug/kg) significantly reduced the arthritis index (comparing P＜0.05 with model group) of rat model on the 19th, 25 day to WANTONG JINGU PIAN after sensitization.
Three, the analgesic activity of unblocking collaterals to treat arthritis cataplasma
1, the unblocking collaterals to treat arthritis cataplasma is to the analgesic activity of the hot whipping of mice
1.1 method
60 of mices, stratified random is divided into normal control group (giving substrate), the high, medium and low dosage group (2.88g crude drug/kg of unblocking collaterals to treat arthritis cataplasma, 1.44g crude drug/kg, 0.72g crude drug/kg), (1.44g crude drug/kg), (1.2g cream/kg is equivalent to 12mg diclofenac sodium/kg) to positive drug diclofenac group to the WANTONG JINGU PIAN group.Removing the WANTONG JINGU PIAN group is gastric infusion, and all the other are percutaneous dosing.Measure the threshold of pain (mice is immersed in 50 ℃ of warm water to the time that afterbody gets rid of, to call TFL in the following text from the tail point) of each mice before the administration earlier with stopwatch, 1h behind the single-dose, 2h, 4h, 6h measure TFL respectively, calculate the analgesia rate, organize a t check.
Analgesia rate=(TFL-threshold of pain)/threshold of pain * 100%
1.2 result
High dose unblocking collaterals to treat arthritis cataplasma (1h～6h after the administration of 2.88g crude drug/kg), the whipping time lengthening (compares with matched group, P＜0.05, P＜0.01), analgesic effect is remarkable, middle dosage unblocking collaterals to treat arthritis cataplasma (2h～6h after the administration of 1.44g crude drug/kg), analgesic effect significantly (compares with matched group, P＜0.01), unblocking collaterals to treat arthritis cataplasma low dosage (0.72g crude drug/kg) and tablet (and after the administration of 1.44g crude drug/kg) 1h～4h analgesic effect significantly (with matched group relatively, P＜0.05).
2, logical muscles and bones cataplasma is to the influence of mice acetic acid twisting
2.1 material
Mice, the Kunming kind, male, body weight 18～22g is provided by the department of the Chinese Academy of Sciences of Department Of Medicine, Peking University's laboratory animal section, the quality certification number: SCXK (capital) 2002-0001.
2.2 medicine and reagent
Unblocking collaterals to treat arthritis cataplasma (4.797g crude drug/g extractum) is provided lot number 20050615 by the Drug Manufacturing Room of China Academy Of Traditional Chinese Medicine Traditional Chinese Medicine Research Institute; WANTONG JINGU PIAN (0.5588g crude drug/sheet) is provided lot number 041002 by TongHua WanTong Pharmacy Co., Ltd; Diclofenac, Novartis Pharma AG, lot number 05103.Acetic acid, analytical pure, Beijing Chemical Plant, lot number 20010809.
2.3 method
60 of mices, stratified random is divided into model control group (giving substrate), the high, medium and low dosage group (2.88g crude drug/kg of unblocking collaterals to treat arthritis cataplasma, 1.44g crude drug/kg, 0.72g crude drug/kg), the WANTONG JINGU PIAN group (the 1.44g crude drug/kg), positive drug diclofenac group (12mg/kg), except that WANTONG JINGU PIAN was gastric infusion, all the other were percutaneous dosing.Behind the single-dose 1h, lumbar injection 0.7% acetum 0.1ml/10g, record give behind the acetic acid and to turn round the body number of times in the 15min.Organize a t check.
2.4 result
Unblocking collaterals to treat arthritis cataplasma height, middle dosage (2.88g crude drug/kg, 1.44g crude drug/kg) and tablet (1.44g crude drug/kg) all can obviously reduce the mouse writhing number of times (with model group relatively, P＜0.05), analgesic activity is arranged.
Four, the function of promoting blood circulation to disperse blood clots of unblocking collaterals to treat arthritis cataplasma
1. the unblocking collaterals to treat arthritis cataplasma is to hemorheological influence
1.1 material
Animal: the SD rat, male, body weight 190～210g is provided by the department of the Chinese Academy of Sciences of Department Of Medicine, Peking University's laboratory animal section.The quality certification number: SCXK (capital) 2002-0001,
1.2 medicine, reagent and instrument
Unblocking collaterals to treat arthritis cataplasma (4.797g crude drug/g extractum) is provided lot number 20050615 by the Drug Manufacturing Room of China Academy Of Traditional Chinese Medicine Traditional Chinese Medicine Research Institute; WANTONG JINGU PIAN (0.5588g crude drug/g sheet) is provided lot number 041002 by TongHua WanTong Pharmacy Co., Ltd; Diclofenac, Novartis Pharma AG, lot number 05103; Carrageenin, Sigma company, lot number 121K1653.
The whole blood viscosity meter, LBY-N6A, the general Lik-Sang in Beijing instrument company produces; Platelet aggregation instrument, DIC-PA3210, Japan produces; High speed capillary tube centrifuge, KH-120A, Japan produces; Centrifuge, LXZ-II, medical analytical instrument factory in Shanghai produces;
1.3 method
60 of rats, stratified random is divided into model control group (giving substrate), the high, medium and low dosage group (2.4g crude drug/kg of unblocking collaterals to treat arthritis cataplasma, 1.2g crude drug/kg, 0.6g ((1.2g cream/kg is equivalent to that the 12mg diclofenac sodium/kg), other establishes 10 of normal control groups for 1.2g crude drug/kg) and positive drug diclofenac group for crude drug/kg), WANTONG JINGU PIAN group.Except that WANTONG JINGU PIAN is to irritate the stomach, all the other are percutaneous dosing, successive administration 3 days, and every day 1 time is behind the last administration 1h, at its right hind foot sole of the foot subcutaneous injection 1% carrageenin 100 μ l of portion.
Behind the animal last administration 1h, carry out platelet aggregation and Determination of Blood Rheology, behind the rat anesthesia, through abdominal aortic blood, with 3.8% sodium citrate (1: 9) anticoagulant, after making platelet rich plasma and platelet poor plasma with centrifuge, measure the platelet aggregation percentage rate with platelet aggregation instrument in proportion; Other gets blood and puts in the mensuration cup of rotating cylinder viscometer, measures the whole blood viscosity under the different shear rates; Suck in the capillary tube of whole blood viscosity meter the plasma viscosity when measuring 37 ℃ with above-mentioned platelet poor plasma; With high speed centrifugation after the capillary tube draw blood 5 minutes, read the hematocrit value with the packed cell volume counting chamber; With the capillary tube that runs through the hematocrit value after treatment, go out heat sink proteic content with the counting dipstick metering.
1.4 result
(2.4g crude drug/kg, 1.2g crude drug/kg) significantly reduce platelet aggregation rate (comparing P＜0.01 with model group) and plasma viscosity (comparing P＜0.05 with model group) for unblocking collaterals to treat arthritis cataplasma height, middle dosage.It is that 10/s, the 50/s whole blood viscosity during with 200/s (is compared with model group that unblocking collaterals to treat arthritis cataplasma high dose can significantly reduce shear rate, P＜0.01), dosage in the unblocking collaterals to treat arthritis cataplasma ((compare with model group by the whole blood viscosity when 1.2g crude drug/kg) can significantly reduce shear rate and is 10/s, 50/s, P＜0.05), three dosage of unblocking collaterals to treat arthritis cataplasma can reduce heat sink proteic content with tablet and (compare with model group, P＜0.05, P＜0.01).
2. the unblocking collaterals to treat arthritis cataplasma causes the influence that the abdominal cavity capillary permeability raises to mouse peritoneal injection acetic acid.
2.1 material
Animal: mice, the Kunming kind, male, body weight 18～22g is provided by the department of the Chinese Academy of Sciences of Department Of Medicine, Peking University's laboratory animal section, the quality certification number: SCXK (capital) 2002-0001.
2.2 medicine and reagent
Unblocking collaterals to treat arthritis cataplasma (4.797g crude drug/g extractum) is provided lot number 20050615 by the Drug Manufacturing Room of China Academy Of Traditional Chinese Medicine Traditional Chinese Medicine Research Institute; WANTONG JINGU PIAN (0.5588g crude drug/sheet) is provided lot number 041002 by TongHua WanTong Pharmacy Co., Ltd; Diclofenac, Novartis Pharma AG, lot number 05103; Acetic acid, analytical pure, Beijing Chemical Plant, lot number 20010809; The ivens orchid, Chemical Reagent Co., Ltd., Sinopharm Group's (import packing), lot number F20040709.
2.3 method
60 of mices, stratified random is divided into model control group (give substrate), the high, medium and low dosage group of unblocking collaterals to treat arthritis cataplasma (2.88g crude drug/kg, 1.44g crude drug/kg, 0.72g crude drug/kg), WANTONG JINGU PIAN (1.44g crude drug/kg) and positive drug diclofenac group (12mg/kg), wherein WANTONG JINGU PIAN is a gastric infusion, and all the other are percutaneous dosing.Behind the single-dose 1h, lumbar injection 0.7% acetum 0.2ml/ only, the blue normal saline solution 0.1ml/10g of tail vein injection 0.5% ivens body weight behind the 30min, after 20min mice being taken off vertebra puts to death, intraperitoneal injection normal saline 6ml, gently rub mouse web portion, so that the intraperitoneal dyestuff fully is dissolved in the normal saline and mix homogeneously, puncture into the abdominal cavity with No. 6 syringe needles then, the careful 4ml liquid of drawing, every pipe centrifugal 3000rpm is behind the 10min, get supernatant and measure the optical density value at 590nm place, be converted into dyestuff content according to standard curve.
2.4 result
The results are shown in Table 15, Dichlorodiphenyl Acetate causes in the experimental therapy that the abdominal cavity capillary permeability raises, and (2.88g crude drug/kg, 1.44g crude drug/kg) significantly reduce capillary permeability (comparing P＜0.01 with model group) for unblocking collaterals to treat arthritis cataplasma height, middle dosage.
Table 15 unblocking collaterals to treat arthritis cataplasma oozes out the influence (x ± s) of dyestuff content to mouse peritoneal
Annotate: compare with model control group,
*P＜0.01.
Brief summary and discussion:
The unblocking collaterals to treat arthritis cataplasma has anti-soft tissue injury, antiinflammatory, analgesia, and the effect of blood circulation promoting and blood stasis dispelling
The unblocking collaterals to treat arthritis cataplasma all has the effect of antagonism soft tissue injury, in the treatment of rat skin ecchymosis, can significantly accelerate the dissipation and the improvement of skin ecchymosis; In the treatment to the traumatic soft tissue injury of rat, can obviously improve and hinder the limb degree of injury, alleviate pathological changes such as wound local organization blood stasis, swelling and cell infiltration.
The unblocking collaterals to treat arthritis cataplasma has tangible antiinflammatory action, Oleum Tiglii is caused mice ear, carrageenin cause rat paw edema, Freund's complete adjuvant and cause the arthroncus that rat immunity arthritis causes significant inhibitory effect is arranged.
The unblocking collaterals to treat arthritis cataplasma also has analgesic activity preferably, and the pain reaction that mice thermostimulation tail-flick method and acetic acid twisting method are caused has significant inhibitory effect.
The unblocking collaterals to treat arthritis cataplasma also has the effect of blood circulation promoting and blood stasis dispelling, can reduce whole blood viscosity, and the abdominal cavity capillary permeability raises due to the anticoagulant, Dichlorodiphenyl Acetate all inhibitory action.
The unblocking collaterals to treat arthritis cataplasma contains toxic herbs such as Radix Aconiti Preparata, Radix Aconiti Kusnezoffii Preparata, Semen Strychni, as the external cataplasma through the skin administration, not only avoided oral formulations that gastrointestinal is stimulated, the percutaneous absorption process will inevitably alleviate greatly to the toxicity of whole body relatively slowly.Skin allergy, skin irritation reaction do not appear yet.Therefore, behind the novel form percutaneous dosing, raising to a certain degree drug safety, for data for clinical drug use provides new selection.
The present invention is a kind of expelling wind and cold, removing obstruction in the collateral to relieve pain.Be used for arthromyodynia, lumbago and skelalgia, the muscle arthralgia, joint stuffiness, and the external used medicine of scapulohumeral periarthritis, cervical spondylosis, rheumatic arthritis, rheumatoid arthritis, the unblocking collaterals to treat arthritis cataplasma contains toxic herbs such as Radix Aconiti Preparata, Radix Aconiti Kusnezoffii Preparata, Semen Strychni, as the external cataplasma through the skin administration, not only avoided oral formulations that gastrointestinal is stimulated, the percutaneous absorption process will inevitably alleviate greatly to the toxicity of whole body relatively slowly.Skin allergy, skin irritation reaction do not appear yet.Therefore, behind the novel form percutaneous dosing, raising to a certain degree drug safety, for data for clinical drug use provides new selection.
Do not see obvious adverse reaction.
The specific embodiment
Embodiment 1
Radix Aconiti Preparata 7 Radix Aconiti Kusnezoffii Preparatas, 7 Semen Strychni (system) 7
Herba Epimedii 7 Radix Achyranthis Bidentataes 7 Rhizoma Et Radix Notopterygiis 7
Rhizoma Osmundae 7 Cortex Phellodendris 7 Zaocyss 7
Cornu Cervi Pantotrichum 4 Radix Dipsacis 7 Fructus Mumes 7
Herba Asari 2 Herba Ephedraes 7 Ramulus Cinnamomi 7
Flos Carthami 7 Radix Et Caulis Acanthopanacis Senticosis 7 Flos Loniceraes 7
Pheretima 7 Herba Taxillis 7 Radix Glycyrrhizaes 7
Rhizoma Drynariae (scalding) 7 Cortex Illiciis 7 Myrrha (processed) 7
Radix Ginseng Rubra 7
Formulation method is made spray of the present invention routinely.
Embodiment 2
Radix Aconiti Preparata 15 Radix Aconiti Kusnezoffii Preparatas, 15 Semen Strychni (system) 15
Herba Epimedii 15 Radix Achyranthis Bidentataes 15 Rhizoma Et Radix Notopterygiis 15
Rhizoma Osmundae 15 Cortex Phellodendris 15 Zaocyss 15
Cornu Cervi Pantotrichum 12 Radix Dipsacis 15 Fructus Mumes 15
Herba Asari 6 Herba Ephedraes 15 Ramulus Cinnamomi 15
Flos Carthami 15 Radix Et Caulis Acanthopanacis Senticosis 15 Flos Loniceraes 15
Pheretima 15 Herba Taxillis 15 Radix Glycyrrhizaes 15
Rhizoma Drynariae (scalding) 15 Cortex Illiciis 15 Myrrha (processed) 15
Radix Ginseng Rubra 15
Make liniment of the present invention according to a conventional method
Embodiment 3
Radix Aconiti Preparata 20 Radix Aconiti Kusnezoffii Preparatas, 20 Semen Strychni (system) 20
Herba Epimedii 20 Radix Achyranthis Bidentataes 20 Rhizoma Et Radix Notopterygiis 20
Rhizoma Osmundae 20 Cortex Phellodendris 20 Zaocyss 20
Cornu Cervi Pantotrichum 14 Radix Dipsacis 20 Fructus Mumes 20
Herba Asari 8 Herba Ephedraes 20 Ramulus Cinnamomi 20
Flos Carthami 20 Radix Et Caulis Acanthopanacis Senticosis 20 Flos Loniceraes 20
Pheretima 20 Herba Taxillis 20 Radix Glycyrrhizaes 20
Rhizoma Drynariae (scalding) 20 Cortex Illiciis 20 Myrrha (processed) 20
Radix Ginseng Rubra 20
Make capsule of the present invention according to a conventional method.
Embodiment 4
Radix Aconiti Preparata 23 Radix Aconiti Kusnezoffii Preparatas, 23 Semen Strychni (system) 23
Herba Epimedii 23 Radix Achyranthis Bidentataes 23 Rhizoma Et Radix Notopterygiis 23
Rhizoma Osmundae 23 Cortex Phellodendris 23 Zaocyss 23
Cornu Cervi Pantotrichum 16 Radix Dipsacis 23 Fructus Mumes 23
Herba Asari 10 Herba Ephedraes 23 Ramulus Cinnamomi 23
Flos Carthami 23 Radix Et Caulis Acanthopanacis Senticosis 23 Flos Loniceraes 23
Pheretima 23 Herba Taxillis 23 Radix Glycyrrhizaes 23
Rhizoma Drynariae (scalding) 23 Cortex Illiciis 23 Myrrha (processed) 23
Radix Ginseng Rubra 23
Make tablet of the present invention according to a conventional method.
Embodiment 5
Radix Aconiti Preparata 9.64g Radix Aconiti Kusnezoffii Preparata 9.64g Semen Strychni (system) 9.64g
Herba Epimedii 9.64g Radix Achyranthis Bidentatae 9.64g Rhizoma Et Radix Notopterygii 9.64g
Rhizoma Osmundae 9.64g Cortex Phellodendri 9.64g Zaocys 9.64g
Cornu Cervi Pantotrichum 6.43g Radix Dipsaci 9.64g Fructus Mume 9.64g
Herba Asari 4.82g Herba Ephedrae 9.64g Ramulus Cinnamomi 9.64g
Flos Carthami 9.64g Radix Et Caulis Acanthopanacis Senticosi 9.64g Flos Lonicerae 9.64g
Pheretima 9.64g Herba Taxilli 9.64g Radix Glycyrrhizae 9.64g
Rhizoma Drynariae (scalding) 9.64g Cortex Illicii 9.64g Myrrha (processed) 9.64g
Radix Ginseng Rubra 9.64g
Above 25-component medical material, Rhizoma Et Radix Notopterygii, Herba Asari, Myrrha, Ramulus Cinnamomi, Radix Ginseng, Radix Et Caulis Acanthopanacis Senticosi, Cornu Cervi Pantotrichum seven flavors soaked 2 hours earlier, and the reuse vapor distillation extracts volatile oil, and volatile oil, medicinal liquid device are in addition preserved; Medicinal residues and Radix Dipsaci, Rhizoma Drynariae, Radix Aconiti Preparata, grass system crow, Semen Strychni (processed), Cortex Phellodendri, Rhizoma Osmundae, Cortex Illicii, Pheretima, 10 flavor medical materials one such as Herba Taxilli are reinstated 70% ethanol extraction 3 times, and alcohol adding amount is 6 times/time, 1.5 hours/time extraction times.Leach alcohol extract, decompression recycling ethanol is to the device preservation in addition of relative density 1.28-1.30 (50 ℃) extractum.Herba Epimedii, Radix Glycyrrhizae, Radix Achyranthis Bidentatae, Flos Lonicerae, Fructus Mume, Herba Ephedrae, Flos Carthami, Zaocys adds 8 times of water, extracts 3 times, extracts 1.5 hours at every turn.Medicinal liquid merges with the medicinal liquid of carrying the volatile oil medical material, and being evaporated to relative density is 1.045～1.065 (50 ℃), the centrifugal removal of impurity, and supernatant is evaporated to relative density 1.28-1.30 (50 ℃) and merges with alcohol-extracted extract.Took by weighing sodium polyacrylate, carbomer, gelatin, Resina persicae, glycerol, sodium hydroxide, distilled water (3.6: 4.2: 6.0: 9.0: 30: 1.5: 45), make substrate, add volatile oil, azone, propylene glycol each 1%, mud moor gold ethyl ester, propyl ester each 0.05%, EDTA-Na0.01%, Chinese medical concrete, mix into glue, coating, cutting, packing.
Claims (10)
1. an expelling wind and cold, removing obstruction in the collateral to relieve pain external used medicine is characterized in that it is the Chinese medicine by the following weight parts proportioning:
Radix Aconiti Preparata 7-23 Radix Aconiti Kusnezoffii Preparata 7-23 Semen Strychni 7-23
Herba Epimedii 7-23 Radix Achyranthis Bidentatae 7-23 Rhizoma Et Radix Notopterygii 7-23
Rhizoma Osmundae 7-23 Cortex Phellodendri 7-23 Zaocys 7-23
Cornu Cervi Pantotrichum 4-16 Radix Dipsaci 7-23 Fructus Mume 7-23
Herba Asari 2-10 Herba Ephedrae 7-23 Ramulus Cinnamomi 7-23
Flos Carthami 7-23 Radix Et Caulis Acanthopanacis Senticosi 9.64g Flos Lonicerae 7-23
Pheretima 7-23 Herba Taxilli 7-23 Radix Glycyrrhizae 7-23
Rhizoma Drynariae 7-23 Cortex Illicii 7-23 Myrrha 7-23
Radix Ginseng Rubra 7-23
2. a kind of expelling wind and cold according to claim 1, removing obstruction in the collateral to relieve pain external used medicine is characterized in that, the weight portion proportioning of raw material of Chinese medicine is:
Radix Aconiti Preparata 7 Radix Aconiti Kusnezoffii Preparatas 7 Semen Strychni 7
Herba Epimedii 7 Radix Achyranthis Bidentataes 7 Rhizoma Et Radix Notopterygiis 7
Rhizoma Osmundae 7 Cortex Phellodendris 7 Zaocyss 7
Cornu Cervi Pantotrichum 4 Radix Dipsacis 7 Fructus Mumes 7
Herba Asari 2 Herba Ephedraes 7 Ramulus Cinnamomi 7
Flos Carthami 7 Radix Et Caulis Acanthopanacis Senticosis 7 Flos Loniceraes 7
Pheretima 7 Herba Taxillis 7 Radix Glycyrrhizaes 7
Rhizoma Drynariae 7 Cortex Illiciis 7 Myrrhas 7
Radix Ginseng Rubra 7
3. a kind of expelling wind and cold according to claim 1, removing obstruction in the collateral to relieve pain external used medicine is characterized in that, the weight portion proportioning of raw material of Chinese medicine is:
Radix Aconiti Preparata 15 Radix Aconiti Kusnezoffii Preparatas 15 Semen Strychni 15
Herba Epimedii 15 Radix Achyranthis Bidentataes 15 Rhizoma Et Radix Notopterygiis 15
Rhizoma Osmundae 15 Cortex Phellodendris 15 Zaocyss 15
Cornu Cervi Pantotrichum 12 Radix Dipsacis 15 Fructus Mumes 15
Herba Asari 6 Herba Ephedraes 15 Ramulus Cinnamomi 15
Flos Carthami 15 Radix Et Caulis Acanthopanacis Senticosis 15 Flos Loniceraes 15
Pheretima 15 Herba Taxillis 15 Radix Glycyrrhizaes 15
Rhizoma Drynariae 15 Cortex Illiciis 15 Myrrhas 15
Radix Ginseng Rubra 15
4. a kind of expelling wind and cold according to claim 1, removing obstruction in the collateral to relieve pain external used medicine is characterized in that the weight portion proportioning of raw material of Chinese medicine is:
Radix Aconiti Preparata 20 Radix Aconiti Kusnezoffii Preparatas 20 Semen Strychni 20
Herba Epimedii 20 Radix Achyranthis Bidentataes 20 Rhizoma Et Radix Notopterygiis 20
Rhizoma Osmundae 20 Cortex Phellodendris 20 Zaocyss 20
Cornu Cervi Pantotrichum 14 Radix Dipsacis 20 Fructus Mumes 20
Herba Asari 8 Herba Ephedraes 20 Ramulus Cinnamomi 20
Flos Carthami 20 Radix Et Caulis Acanthopanacis Senticosis 20 Flos Loniceraes 20
Pheretima 20 Herba Taxillis 20 Radix Glycyrrhizaes 20
Rhizoma Drynariae 20 Cortex Illiciis 20 Myrrhas 20
Radix Ginseng Rubra 20
5. a kind of expelling wind and cold according to claim 1, removing obstruction in the collateral to relieve pain external used medicine is characterized in that, the weight portion proportioning of raw material of Chinese medicine is:
Radix Aconiti Preparata 23 Radix Aconiti Kusnezoffii Preparatas 23 Semen Strychni 23
Herba Epimedii 23 Radix Achyranthis Bidentataes 23 Rhizoma Et Radix Notopterygiis 23
Rhizoma Osmundae 23 Cortex Phellodendris 23 Zaocyss 23
Cornu Cervi Pantotrichum 16 Radix Dipsacis 23 Fructus Mumes 23
Herba Asari 10 Herba Ephedraes 23 Ramulus Cinnamomi 23
Flos Carthami 23 Radix Et Caulis Acanthopanacis Senticosis 23 Flos Loniceraes 23
Pheretima 23 Herba Taxillis 23 Radix Glycyrrhizaes 23
Rhizoma Drynariae 23 Cortex Illiciis 23 Myrrhas 23
Radix Ginseng Rubra 23
6. a kind of expelling wind and cold according to claim 1, removing obstruction in the collateral to relieve pain external used medicine is characterized in that, the weight portion proportioning of raw material of Chinese medicine is:
Radix Aconiti Preparata 9.64g Radix Aconiti Kusnezoffii Preparata 9.64g Semen Strychni 9.64g
Herba Epimedii 9.64g Radix Achyranthis Bidentatae 9.64g Rhizoma Et Radix Notopterygii 9.64g
Rhizoma Osmundae 9.64g Cortex Phellodendri 9.64g Zaocys 9.64g
Cornu Cervi Pantotrichum 6.43g Radix Dipsaci 9.64g Fructus Mume 9.64g
Herba Asari 4.82g Herba Ephedrae 9.64g Ramulus Cinnamomi 9.64g
Flos Carthami 9.64g Radix Et Caulis Acanthopanacis Senticosi 9.64g Flos Lonicerae 9.64g
Pheretima 9.64g Herba Taxilli 9.64g Radix Glycyrrhizae 9.64g
Rhizoma Drynariae 9.64g Cortex Illicii 9.64g Myrrha 9.64g
Radix Ginseng Rubra 9.64g
7. according to each described a kind of expelling wind and cold of claim 1-6, removing obstruction in the collateral to relieve pain external used medicine, it is characterized in that this medicine is capsule, crust cloth preparation, tablet, spray or liniment.
8. according to each described a kind of expelling wind and cold of claim 1-6, removing obstruction in the collateral to relieve pain external used medicine, it is characterized in that: this medicine is a cataplasma.
9. according to the preparation method of each described a kind of expelling wind and cold of claim 1-6, removing obstruction in the collateral to relieve pain external used medicine, it is characterized in that comprising the following steps:
Above 25-component medical material, Rhizoma Et Radix Notopterygii, Herba Asari, Myrrha, Ramulus Cinnamomi, Radix Ginseng, Radix Et Caulis Acanthopanacis Senticosi, Cornu Cervi Pantotrichum seven flavors soaked 2 hours earlier, and the reuse vapor distillation extracts volatile oil, and volatile oil, medicinal liquid device are in addition preserved; Medicinal residues and Radix Dipsaci, Rhizoma Drynariae, Radix Aconiti Preparata, grass system crow, Semen Strychni (processed), Cortex Phellodendri, Rhizoma Osmundae, Cortex Illicii, Pheretima, 10 flavor medical materials one such as Herba Taxilli are reinstated 70% ethanol extraction 3 times, and alcohol adding amount is 6 times/time, 1.5 hours/time extraction times, leach alcohol extract, decompression recycling ethanol is to the device preservation in addition of relative density 1.28-1.30 extractum, Herba Epimedii, Radix Glycyrrhizae, Radix Achyranthis Bidentatae, Flos Lonicerae, Fructus Mume, Herba Ephedrae, Flos Carthami, Zaocys, add 8 times of water, extract 3 times, extracted 1.5 hours at every turn, medicinal liquid merges with the medicinal liquid of carrying the volatile oil medical material, being evaporated to relative density is 1.045～1.065, the centrifugal removal of impurity, supernatant are evaporated to relative density 1.28-1.30 and alcohol-extracted extract merges, and technology is made acceptable preparation formulation on the pharmaceutics routinely then.
10. the preparation method of a kind of expelling wind and cold according to claim 9, removing obstruction in the collateral to relieve pain external used medicine is characterized in that comprising the following steps:
Above 25-component medical material, Rhizoma Et Radix Notopterygii, Herba Asari, Myrrha, Ramulus Cinnamomi, Radix Ginseng, Radix Et Caulis Acanthopanacis Senticosi, Cornu Cervi Pantotrichum seven flavors soaked 2 hours earlier, and the reuse vapor distillation extracts volatile oil, and volatile oil, medicinal liquid device are in addition preserved; Medicinal residues and Radix Dipsaci, Rhizoma Drynariae, Radix Aconiti Preparata, grass system crow, Semen Strychni (processed), Cortex Phellodendri, Rhizoma Osmundae, Cortex Illicii, Pheretima, 10 flavor medical materials one such as Herba Taxilli are reinstated 70% ethanol extraction 3 times, and alcohol adding amount is 6 times/time, 1.5 hours/time extraction times, leach alcohol extract, decompression recycling ethanol is to the device preservation in addition of relative density 1.28-1.30 extractum, Herba Epimedii, Radix Glycyrrhizae, Radix Achyranthis Bidentatae, Flos Lonicerae, Fructus Mume, Herba Ephedrae, Flos Carthami, Zaocys adds 8 times of water, extracts 3 times, the each extraction 1.5 hours, medicinal liquid merges with the medicinal liquid of carrying the volatile oil medical material, and being evaporated to relative density is 1.045～1.065, the centrifugal removal of impurity, supernatant are evaporated to relative density 1.28-1.30 and alcohol-extracted extract merges, and takes by weighing sodium polyacrylate, carbomer, gelatin, Resina persicae, glycerol, sodium hydroxide, distilled water, make substrate, add volatile oil, azone, propylene glycol each 1%, mud moor gold ethyl ester, propyl ester each 0.05%, EDTA-Na0.01%, Chinese medical concrete mixes into glue, coating, cutting, packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009101469330A CN101559128A (en) | 2009-06-08 | 2009-06-08 | Externally used medicine for expelling wind and clearing away cold, activating meridians to stop pain and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009101469330A CN101559128A (en) | 2009-06-08 | 2009-06-08 | Externally used medicine for expelling wind and clearing away cold, activating meridians to stop pain and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101559128A true CN101559128A (en) | 2009-10-21 |
Family
ID=41218219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2009101469330A Pending CN101559128A (en) | 2009-06-08 | 2009-06-08 | Externally used medicine for expelling wind and clearing away cold, activating meridians to stop pain and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101559128A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335304A (en) * | 2010-07-20 | 2012-02-01 | 天津中新药业集团股份有限公司达仁堂制药厂 | Chinese medicine composition for dispelling wind, removing dampness, invigorating blood circulation, and relieving pain and preparation method thereof |
| CN102370952A (en) * | 2011-11-22 | 2012-03-14 | 王洪强 | Traditional Chinese medicine for treating rheumatism and rheumatoid disease |
| CN102988833A (en) * | 2012-12-20 | 2013-03-27 | 孟凡玉 | Traditional Chinese medicine composition for treating rheumatism |
| US20130304167A1 (en) * | 2012-05-14 | 2013-11-14 | Tuming You | Heat Patch for Pain |
| CN103948724A (en) * | 2014-04-23 | 2014-07-30 | 通化万通药业股份有限公司 | Muscle and bone plaster |
| CN104306946A (en) * | 2014-11-10 | 2015-01-28 | 河南中医学院 | Traditional Chinese medicine plaster for treating pain |
| CN107982375A (en) * | 2017-12-04 | 2018-05-04 | 黑龙江参鸽药业有限公司 | A kind of chill is double from the preparation method for turning piece |
-
2009
- 2009-06-08 CN CNA2009101469330A patent/CN101559128A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335304A (en) * | 2010-07-20 | 2012-02-01 | 天津中新药业集团股份有限公司达仁堂制药厂 | Chinese medicine composition for dispelling wind, removing dampness, invigorating blood circulation, and relieving pain and preparation method thereof |
| CN102370952A (en) * | 2011-11-22 | 2012-03-14 | 王洪强 | Traditional Chinese medicine for treating rheumatism and rheumatoid disease |
| US20130304167A1 (en) * | 2012-05-14 | 2013-11-14 | Tuming You | Heat Patch for Pain |
| CN102988833A (en) * | 2012-12-20 | 2013-03-27 | 孟凡玉 | Traditional Chinese medicine composition for treating rheumatism |
| CN102988833B (en) * | 2012-12-20 | 2014-04-23 | 孟凡玉 | Traditional Chinese medicine composition for treating rheumatism |
| CN103948724A (en) * | 2014-04-23 | 2014-07-30 | 通化万通药业股份有限公司 | Muscle and bone plaster |
| CN104306946A (en) * | 2014-11-10 | 2015-01-28 | 河南中医学院 | Traditional Chinese medicine plaster for treating pain |
| CN107982375A (en) * | 2017-12-04 | 2018-05-04 | 黑龙江参鸽药业有限公司 | A kind of chill is double from the preparation method for turning piece |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ge et al. | Anti-inflammatory and blood stasis activities of essential oil extracted from Artemisia argyi leaf in animals | |
| CN102847063B (en) | Traditional Chinese medicinal composition for treating qi and blood deficiency blood stasis type diabetic feet, and its preparation method | |
| CN101559128A (en) | Externally used medicine for expelling wind and clearing away cold, activating meridians to stop pain and preparation method thereof | |
| WO2006076844A1 (en) | Traditional chinese medicament for treating injuries from falls, rheumatism and ostealgia and method for manufacture thereof | |
| CN100560101C (en) | A kind of expelling wind and cold, removing obstruction in the collateral to relieve pain external used medicine and preparation method thereof | |
| CN104274788A (en) | Traditional Chinese medicine composition for treating morbid leucorrhea due to liver-fire and damp-heat in women and preparation method of traditional Chinese medicine composition | |
| CN103520593B (en) | Chinese herba preparation for treating trichomonas vaginitis and preparation method thereof | |
| CN102698014B (en) | Chinese medicinal composition for treating bone-related diseases and preparation method and application thereof | |
| CN102772712B (en) | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot | |
| CN101711835B (en) | Formula of traditional Chinese medicines for treating soft tissue injury and method for preparing preparation thereof | |
| CN103720841B (en) | A kind of Chinese medicine preparation for the treatment of chronic suppurative otitis media and preparation method thereof | |
| CN102670977B (en) | Chinese medicinal composition for treating arthralgia, preparation method and applications of Chinese medicinal composition | |
| CN101829291B (en) | Traditional Chinese medicine preparation for treating rheumatism and preparation method thereof | |
| CN101816670A (en) | New medical application of beta-sodium aescinate | |
| CN1895641A (en) | Medicinal preparation with blood-activating, anti-inflammatory and analgesic functions and its making method | |
| CN103721138A (en) | External traditional Chinese medicinal preparation for treating acne rosacea and preparation method thereof | |
| CN103316166A (en) | Tibetan medicine for treating hemorrhoids and preparation method thereof | |
| CN103948718B (en) | A kind of Chinese medicine for glycosuria gravidarum patient pruritus vulvae and preparation method thereof | |
| CN103623122B (en) | A kind of Chinese medicine for hemorrhoid and preparation method thereof | |
| CN105535292A (en) | Traditional Chinese medicine preparation for treating postpartum urinary retention and preparation method thereof | |
| CN104547580A (en) | Traditional Chinese medicine preparation for treating kidney-deficiency postpartum rheumatic and production method of traditional Chinese medicine preparation | |
| CN105213669A (en) | A kind of Chinese medicine and preparation method for the treatment of nodular vasculitis | |
| CN104306783A (en) | Traditional Chinese medicine for treating hemophilia and preparation method thereof | |
| CN108815268A (en) | A kind of external application promotees the Chinese medicine ointment formulation and preparation method thereof of union of wounded skin | |
| CN104587038B (en) | A kind of preparation method of the Chinese medicine composition acted on anti-inflammatory analgetic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20091021 |